A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
A 61-year-old male patient was simultaneously diagnosed with lung adenocarcinoma and inflammatory myofibroblastic tumor (IMT). The lung adenocarcinoma and IMT harbored two distinct types of ALK translocation, LOC101927285-ALK, and TPM3-ALK, respectively. The ALK Ventana showed strong positivity on both lesions. The patient was therefore given an endobronchial cryotherapy and ALK inhibitor crizotinib. The tumors showed durable response however the left lung adenocarcinoma relapsed at 17th month post-crizotinib treatment. Tissue re-biopsy on the resistant tumor revealed an ALK exon 23 C1156Y missense mutation in addition to LOC101927285-ALK mutation. Further RNA-based sequence uncovered that the noncoding region rearrangement is the fusion mutation of EML4-ALK. The patient was therefore received alectinib, and the tumor exhibited partly response. Overall, it is very rare that two types of pulmonary tumors exist in one patient driven by two distinct ALK fusions, which emphasizes the necessity of gene sequencing in clinical decision-making and individualized therapy.
Abstract
A 61-year-old male patient was simultaneously diagnosed with lung adenocarcinoma and inflammatory myofibroblastic tumor (IMT). The lung adenocarcinoma and IMT harbored two distinct types of ALK translocation, LOC101927285-ALK, and TPM3-ALK, respectively. The ALK Ventana showed strong positivity on both lesions. The patient was therefore given an endobronchial cryotherapy and ALK inhibitor crizotinib. The tumors showed durable response however the left lung adenocarcinoma relapsed at 17th month post-crizotinib treatment. Tissue re-biopsy on the resistant tumor revealed an ALK exon 23 C1156Y missense mutation in addition to LOC101927285-ALK mutation. Further RNA-based sequence uncovered that the noncoding region rearrangement is the fusion mutation of EML4-ALK. The patient was therefore received alectinib, and the tumor exhibited partly response. Overall, it is very rare that two types of pulmonary tumors exist in one patient driven by two distinct ALK fusions, which emphasizes the necessity of gene sequencing in clinical decision-making and individualized therapy.
참고문헌 (8)
- Shackelford RE, "ALK-rearrangements and testing methods in non-small cell lung cancer : a review", Genes Cancer, 5, pp.1~14 (2014)
- Butrynski JE, "Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor", N Engl J Med, 363, pp.1727~1733 (2010)
- Montgomery EA, "Inflammatory myofibroblastic tumors of the urinary tract : a clinicopathologic study of 46cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma", Am J Surg Pathol, 30, pp.1502~1512 (2006)
- Mansfield AS, "Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib", Ann Oncol, 27, pp.2111~2117 (2016)
- Kazandjian D, "FDA approval summary : crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements", Oncologist, 19, pp.e5~11 (2014)
- Du X, "ALK-rearrangement in non-small-cell lung cancer(NSCLC)", Thorac Cancer, 9, pp.423~430 (2018)
- Camidge DR, "Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer : updated results from a phase 1 study", Lancet Oncol, 13, pp.1011~1019 (2012)
- Dono M, "Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma : detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma", Br J Cancer, 110, pp.1058~1065 (2014)